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Nanoparticle-cored dendrimers: functional 
hybrid nanocomposites as new platform for 
drug delivery systems 
V. Brunettia, L. M. Boucheta, and M. C. Strumiab*  
Nanoparticle-cored dendrimers (NCDs) are now offering themselves as versatile carriers 
because of their colloidal stability, tunable membrane properties and ability to encapsulate or 
integrate a broad range of drugs and molecules. This kind of hybrid nanocomposite aims to 
combine the advantage of stimuli-responsive dendritic coating, in order to regulate the drug 
release behaviour under different conditions and improve the biocompatibility and in vivo half-
time circulation of the inorganic nanoparticles. Size, surface chemistry and shape are key 
nanocarrier properties to evaluate. Here, we have reviewed the most recent advances of NCDs 
in drug delivery systems, compared their behaviour with non-dendritic stabilized nanoparticles 
and highlighted their challenges and promising applications in the future. 
Introduction  
Nanoparticles (NPs) are an intriguing class of highly tunable 
nanoscale objects, and are receiving particular attention due to 
their wide range of applications.1-3 NPs usually exhibit size-
related characteristics that differ significantly from those 
observed in bulk materials. Thus, their importance is attributed 
to the fact that they represent a critical link between current 
technologies and future applications due to their small size, 
large surface-to-volume ratio and size dependent properties. 
Metal and semiconductor NPs, as well as hybrid structures 
using polymeric material, have been synthesized and are part of 
the manufacturing of our daily life products for more than a 
decade (scratchproof eyeglasses, crack- resistant paints, anti-
graffiti coatings for walls, transparent sunscreens, stain-
repellent fabrics, self-cleaning windows and ceramic coatings 
for solar cells).4 Today, nanocomposites5-7 with high-
performance applications in numerous fields, such as 
electrochromic devices8 and energy storage,9, 10 make these 
hybrid materials of prime importance. 
 Gold nanoparticles (AuNPs) have been among the most 
extensively studied nanomaterials over a century because of 
their remarkable optical properties related to their plasmon 
absorption and are now heavily utilized in chemistry, biology, 
engineering, and medicine because of their unique optical, 
chemical, electrical, and catalytic properties.11, 12 AuNPs have 
attracted the interest of scientists especially in the areas of  
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photothermal therapy,13 biosensing,14 imaging,15 and drug 
delivery.2 Magnetic nanoparticles (MNPs) have generated 
considerable interest in the scientific world especially in the 
area of biomedicine and technology, particularly in magnetic 
storage media,16 biosensing,17, 18 inks and paints,19 drug 
delivery and contrast agents in magnetic resonance imaging. 20 
NPs are generally synthesized in either aqueous or organic 
solutions and thus require sophisticated coating for stability. 21 
The aggregation processes occur frequently in the colloidal 
systems of metal or semiconductor NPs, and severely restrict 
their utilization in different applications. Thus, in order to 
prevent or slow the aggregation, NPs are usually functionalized 
with a thin shell of monomeric stabilizers, (thiols, carboxylates, 
phosphates or sulfates), synthetic and natural polymers 
(dextran, polythylene glycol (PEG), polyvinylpyrrolidone, 
polyethylene oxide or chitosan), inorganic material (silica), 
liposomes and another class of emerging molecules such as 
dendrimers and dendrons. Organic coatings for biomedical 
applications must contain several bioactive functions that 
ensure biocompatibility, targeting and possible therapeutic care, 
and also prevent the nanoparticles from agglomeration in a 
physiological environment thus favouring ideal biodistribution 
and bioelimination.22  
 Dendrimers are well-defined, highly branched 
macromolecules that can mimic certain properties of micelles 
and liposomes or even highly organized building blocks of 
biological systems. These properties make dendrimers suitable 
for many important application areas, particularly as drug 
carriers.23 Crooks et al reported for the first time the synthesis 
and characterization of dendrimer-encapsulated nanoparticles.24 
These highly organized structures are able to encapsulate 
different metal ions and serve as a template for the formation of 
a wide range of metallic nanostructures including Cu, Ag, Au, 
Pt and Pd.25 The development and research of dendritically 
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stabilized NPs have been an exciting field of investigation due 
to the potential to combine the properties of nanosized core 
with the permeable network of the dendritic branches. Besides, 
the use of these discrete building blocks for biomedical 
purposes is a successful area of research, primarily due to their 
precisely defined structure and composition as well as their 
higher tunable surface chemistry.  
 The use of dendrimers and dendrons as stabilizing agents 
instead of the commonly non-dendritic ligands provides an 
interesting advantage, however, to date there are few reports 
about it. One reason could be the higher costs associated with 
their synthesis and purification. Schlüter et al 26 have shown 
that dendritic molecules present several advantages: (I) the 
dendron structure and size can be accurately controlled during 
synthesis; (II) the classical conical-like dendritic structures are 
of particular interest for ultra-small NPs with very high 
curvature and it is expected to improve steric resistance to 
macromolecular adsorption and particle agglomeration; (III) 
end-group-functionalized dendritic structures have the potential 
for exceptional and quantitatively controlled arrangement of 
(bio)ligands at high surface densities; (IV) the presence of 
hyperbranched arms increases affinity or avidity in multivalent 
(bio)specific interactions relevant to biosensing applications; 
(V) small molecules, such as drugs, could be incorporated into 
the dendritic framework of dendron-stabilized NPs making this 
system attractive as a potential drug release system and (VI) 
stabilization of small NPs with dendrons results in dendronized 
NPs with a relatively thin organic shell and, therefore, a small 
size in the range of 10-30 nm. This latter property is really 
important because it gives them interesting and promising 
material for biomedical applications such as drug delivery 
systems, efficient cell uptake of the NPs, improved tissue 
diffusion, and particularly for targeting tumors via the enhanced 
permeability and retention effect, exploiting the nanoporous 
nature of blood vessels in cancerous tissue.22 Pan et al 27 have 
also demonstrated the effectiveness of the dendrimers for 
systematic control of nanoparticles spacing and developed a 
“bricks and mortar” strategy, in which the colloidal NPs serve 
as the bricks, while dendrimers serve as the mortar. These 
findings confirmed that the assembly process provides control 
over the resulting aggregates, allowing a versatile route to new 
material systems. 
  
Figure 1: Scheme of a Nanoparticle-Cored Dendrimer 
 
The exclusive use of dendrons as stabilizer gives rise to a new 
class of material: Nanoparticle-cored dendrimers (NCDs). 
NCDs are core-shell materials that possess nanometer-sized 
inorganic clusters at the core surrounded by a shell of dendrons 
of different generations which are attached radially to the core 
allowing their stabilization and therefore, impeding aggregation 
(see Figure 1). In this case, the NPs are structural units of the 
dendrimer and are not trapped or encapsulated in dendritic 
pockets.28 The high stability of NCDs protected by dendrons 
with a thiol group was a clear improvement over that of 
dendrimer encapsulated NPs.29  
 
Synthesis, characterization and relevant aspects of NCDs  
 
One of three different synthetic methodologies has been 
generally applied to the generation of NCDs (see Figure 2).30 
The direct method employs the reduction of a metal cation in 
the presence of dendrons bearing suitable moieties at their focal 
point. The functionalities used for this purpose are thiols and 
disulfides groups for the synthesis of NCD with metal-sulfur 
bonds. In recent years a new approach of the direct method, 
which implies the simultaneous reduction of the metal cation in 
the presence of dendrons with a diazonium group at the focal 
point, has been developed. This methodology leads to the 
formation of NCDs with metal-carbon bonds.31 In contrast, the 
ligand-place exchange method is an indirect method comprising 
two-step reactions: the synthesis of monolayer-stabilized NPs 
followed by the replacement of thiolate dendrons. This method 
has the advantage of keeping the core size unchanged during 
the ligand substitution reaction, but the main limitation is, in 
many cases, the difficult access to the thiol-containing 
dendrons. Lastly, the convergent approach is also used, in 
which single or multistep reactions are employed to build 
dendritic architectures onto monolayer-protected NPs. The size 
and material properties of the NCDs were thoroughly 
investigated using a variety of experimental techniques, such as 
spectroscopy, microscopy, electrochemistry, photochemistry, 
etc. The most synthesized NCDs have Au in the core and 
aliphatic or aromatic thiol dendrons in the shell. However, 
dendritic ligands have also been used in the preparation of NCD 
based on magnetic material in the core, particularly magnetite, 
Pd or Ag among other metals, or even semiconductors such as 
CdSe. Concerning the nature of the branching ligands, 
poly(amidoamine), polyarylether and polypropyleneimine 
dendritic wedges are probably the most widely used for 
building NCDs. Some of the novel synthetized NCDs are listed 
in Table 1.  
 
a) Direct method
Mn+ / reductor
or
b) Ligand-exchange
method
+
c) Convergent
approach
+
-SH -S-S- or
 
  
Figure 2: Schematic illustration of the three general synthetic 
strategies 
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The simple synthetic tuning of the dendritic architecture, that is 
the chemical functional group and the extent of the dendritic 
branching, has an important control over the final NCDs 
properties. By using aromatic ether dendrons with either thiol 
or 4-pyridone units at the focal point, Kim 32 and Zheng 33 have 
clearly demonstrated that the dendritic generation could control 
the dimensions of the NCDs.34 Zhong et al 35 have reported that 
unique structural properties of the dendritic arenethiol capping 
molecules not only enable the ability to control size growth of 
AuNPs but also ready surface exchange reaction for surface 
derivatization. Newkome-type ligands as capping molecules 
used for AuNPs synthesis also determine the solubility and 
stability of the NCDs, as well as the characteristics of the core 
through a dendritic control of the size.36 Fox et al 28 using 
Frechet-type dendrons to stabilize the surfaces of gold NPs 
have shown that as dendritic generation increased, the density 
of dendrons on the NPs decreased as a consequence of the 
steric hindrance of the branches. Therefore, for the higher NCD 
generation, a large fraction of the gold surface was not 
passivated and thus available for the catalytic reaction.28 Kumar 
et al also reported the synthesis of Pd NCDs using diazo-
funcionalized Frechet-type dendrons. These core-shell materials 
were successfully used for catalytic applications.37 Smith et al 
34 have reported that using a branched ligand leads to smaller 
and better defined particles rather than using an analogous non-
dendritic one. In addition, building blocks which have ‘long’ 
and ‘short’ branches might be expected to provide a less well-
packed protective monolayer on the surface of the metal core 
hence exposing vertices and defect sites to the etchant 
solution.34 Astruc et al have developed a sensor device by using 
dendrons with ferrocenyl-ended groups onto AuNPs, indicating 
how functionality can be introduced into NCDs giving specific 
properties and applications.38 Moreover, a dendronization 
strategy can also be employed to control the interparticle 
spacing and the optical properties of the NCDs aggregates.39  
Table 1  Some examples of novel synthetized nanoparticle-cored dendrimers 
Core Dendritic arm Remarkable aspects Reference 
Au 
G2-poly(benzyl ether) dendrons 
Non-spherical shape and faceted 
 size: 3-25 nm  (average size = 12 nm) 
40, 41 
G1,G2 and G3        
Superior control of the critical molecular design using dendritic 
functionalization 
42 
Disulfide-focal pi-conjugated dendrons 
Electrical bistability due to a charge transfer interaction between 
Au and dendrons 
43 
G1 Frechet-type dendrons 
Size-controlled NPs depend on the mole ratio (r) of G1: Au. 
Average size (nm): 0.9 (r= 3), 2.8 (r = 1) and 5.1 (r = 0.33) 
44 
G1, G2, G3 and G4 diazo-funcionalized 
Frechet-type dendrons 
Average size (nm): 4.7-5.5  
NCDs with metal-carbon bond. Highly stable 
31 
G1, G2 and G3 Dihydroxy fatty acid –base 
dendrons 
Long-lived nano-hybrids for biological application 45 
G1 and G2 cystamine-focal Newkome-type 
dendrons 
Average size (nm):  G1= 15.2, G2= 17.4  
Relative surface coverage: G1 =0.38, G2=0.19 
46 
Thiol-focal thiophene dendrons 
NPs size = 3 - 5 nm 
Size distribution, and energy-transfer efficiency depend 
sensitively on both alkyl-chain length and dendron size 
47 
G4 Cystamine core polyamidoamine 
dendron 
Support for the covalent attach of tyrosinase,  
useful for cathecol biosensing 
48 
G1 hybrid dendrons containing carborane 
and polyethylene glycol 
Average size= 3.4 - 7.6 nm 
Water soluble and biofunctional NCDs could provide a 
biocompatible platform in therapeutical investigation 
49 
Thiol focal, carbosilane dendrons 
Average size = 2-3 nm 
NCDs are valuable in catalytic processes due to the difficult 
elimination of the dendron shells 
50 
Newkome-type dendrons and L-lysine 
derivatized dendrons 
Effect of dendritic structure on NCDs chemical stability  34, 51 
γ-Fe2O3 
G1 Fluorescein-modiﬁed dendrons 
D1 hydrophobic: alkyl chain and aromatic 
rings; D2 hydrophilic: polyether chain and 
polyamidoamine chains 
The ﬂuorescence measurements of these nanoparticles conﬁrm 
the ability of dendronized molecules to increase the surface 
functionalization, in contrast to the linear analogues. 
52 
Fe3O4 
G2 polyphenylenpyridyl dendrons Magnetically recoverable catalysts 53 
G1 phosphonic acid -focal, hydrophilic oligo 
ethyleneglycol-derivatized dendrons 
D1: three biocompatible tetraethyleneglycol 
chains; 
D2: two tetraethyleneglycol chains and one 
carboxylic acid-ended octaethyleneglycol 
chain 
NCDs did not induce any cytotoxicity. 
In vivo and in vitro Magnetic Resonance Imaging showed that 
the contrast enhancement properties of the NCDs were higher 
than those obtained with commercial polymer-coated NPs. 
22, 54 
CdSe 
Poly(benzyl ether) dendrons Biocompatible platform in therapeutical applications 55, 56 
Oligothiophene dendrons 
NCDs are very soluble and stable in non-polar solvents. They 
exhibit energy transfer, surface plasmon resonance effects, and 
57, 58 
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photoinduced charge transfer interactions (good photovoltaic 
cell) 
CdSe/CdS 
G1 and G2 Tomalia type, thiol-focal 
poly(amidoamine) dendrons  and phosphine 
-focal poly(alkyl ether) dendrons 
G2 dendrons provide adequate surface dense packing to protect 
the NCDs against aggregation for up to 6 months. Useful as 
biological labels due to residual ﬂuorescence intensity  
59, 60 
Pd 
G1, G2 and G3 amino-focalized poly(benzyl 
ether) dendrons 
Average size (nm): G1= 4.7, G2 = 3.2, G3=2.8  
The steric hindrance affects the sizes in the microreactor, 
contrary to the batch tendency 
61 
G1, G2, G3 and G4 diazo-funcionalized 
Frechet-type dendrons 
NCDs with metal-carbon bond. Pd-G1 can catalyze the Suzuki, 
Stille and Hiyama coupling reactions. 
37 
Ag 
G3- anthracenyl-focal poly(amido amine) 
dendrons 
Spherical (15-20 nm) polygonal (20-35 nm) 62 
 
Performance of NCDs in bionanomedicine and as 
nanocarriers in controlled release 
 
Nanotechnology provides a gateway of possibilities for scientists to 
explore their ideas in the biomedical ﬁeld.63, 64 Iron oxide 
nanoparticles,65, 66 quantum dots,67 carbon nanotubes,68 gold 
nanoparticles,69 and silica nanoparticles,70 have previously been 
thoroughly investigated in the imaging setting and are candidate 
nanoplatforms for building up nanoparticle-based theranostics. Thus, 
theranostic nanomedicine is emerging as a promising therapeutic 
paradigm having both imaging and therapeutic agents that execute 
simultaneously diagnostic tests, targeted therapy, and monitor the 
therapeutic response. The resulting nanosystems play a signiﬁcant 
role in the emerging era of nanomedicine and plenty of research 
effort has been devoted towards that goal. 
 An advantage of constructing such function-integrated 
moieties is that many nanoplatforms are already, themselves, 
imaging agents. Their well-developed surface chemistry makes 
it easy to load them with pharmaceutics and promote them to be 
theranostic nanosystems.71, 72 In vivo and in vitro MRI 
measurements showed that the contrast enhancement properties 
of the dendronized NPs were higher than those obtained with 
commercial polymer-coated NPs (Figure 3).22   
 
Figure 3: a) Synthetic scheme of NCDs, b) Spin echo T2 
weighted axial images sequentially acquired before and after an 
injection of 650 µl of NCDs at 7T with a small animal 
dedicated MRI (Biospin – Brücker®). Reproduced from Ref. 22 
with permission from The Royal Society of Chemistry. 
 
 Mesoporous silica nanoparticles (MSNs) have been 
extensively studied and proposed as promising candidates for 
numerous biomedical applications.73, 74 Recently, Gu et al 75 
have reported the design, preparation, characterization and 
biosafety evaluation of peptide dendron functionalized MSNs. 
These nanohybrids were prepared by surface modification of 
MSNs via click reaction of azido-MSNs with alkynyl peptide 
dendrons and in vitro cytotoxicity and in vivo toxicity of the 
nanohybrid were evaluated suggesting that the peptide 
functionalized NPs possessed good biocompatibility due to the 
non-observed significant side effects to normal organs of 
healthy mice.75 Other nanoparticles, such as iron oxide and gold 
nanoparticles  
 
are also the most useful platforms to build theranostic 
nanocarriers which combine both therapeutic and diagnostic 
functions within a single nanostructure. Nevertheless, their 
surface must be functionalized to be appropriate for in vivo 
applications.76 Surface functionalization provides binding sites 
for targeting ligands and for drug uploading.  
 Several crucial factors need to be considered when 
developing a nanomedicine based platform:77 I) identiﬁcation 
of a speciﬁc molecular target, (II) choice of a suitable coating 
candidate, (III) design of the nanocomponent delivery system, 
(IV) characterization of the nanoform, and (V) in vitro and in 
vivo biological activity and pharmacological evaluation. 
Therefore, the surface state of the functionalized NPs largely 
depends on their synthesis routes, dictates the strategies used 
for functionalization and makes them suitable or not for future 
medical applications. 
 Hybrid multifunctional systems with sizes typically ranging 
between 1–100 nm which may deliver the bioactive agent at the 
targeted site with improved therapeutic activity over the free 
form of a bioactive agent is usually named as “nanocarrier”.77 
In particular, NPs have been developed as an important strategy 
to deliver conventional drugs, proteins, vaccines or nucleic 
acids like DNA or RNA. Drug delivery nanosystems should 
provide positive attributes to a ‘free’ drug by improving 
solubility, in vivo stability, and biodistribution.78, 79 AuNPs are 
capable of delivering large biomolecules without restricting 
themselves as carriers of only small molecular drugs. Tunable 
size and functionality make them a useful scaffold for efficient 
recognition and delivery of biomolecules. AuNPs and other 
colloidal drug-delivery systems modify the kinetics, body 
distribution and drug release of an associated drug.80-82 Usually, 
they are of similar size to typical cellular components and 
proteins, and thus may bypass natural mechanical barriers 
possibly leading to adverse tissue reaction.83 In particular, 
positively charged AuNPs are of interest in terms of cellular 
uptake.84 These properties from their cationic nature induce 
electrostatic interactions with negatively charged entities such 
as cell membranes, plasmid DNA, siRNA, or antibodies.85 
While clinically-approved nanoparticles have consistently 
shown value in reducing drug toxicity, their use has not always 
been translated into improved clinical outcomes. This has led to 
the development of “multifunctional” NPs, where additional 
capabilities like targeting and image contrast enhancement 
should be added.86 AuNPs are generally considered nontoxic 
and biocompatible, but Pan et al 87 have reported that AuNPs of 
diameter 1.4 nm capped with triphenylphosphine 
monosulfonate are much more cytotoxic than 15 nm 
nanoparticles of similar chemical composition. These results 
highlight the importance of an optimal size of the nanocarriers. 
Stobiecka et al 88 have shown that the main advantage of poly 
L-lysine coatings in AuNPs is no toxicity related to the ligand 
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release in gene delivery processes in contrast to the thiol-
functionalized AuNPs. Papp et al 89 have demonstrated that a 
sialic-acid-terminated glycerol dendron when chemically 
functionalising small AuNPs provides highly stable NPs that 
show high activity towards the inhibition of inﬂuenza virus 
infection. As the binding of the viral fusion protein 
hemagglutinin to the host cell surface is mediated by sialic acid 
receptors, a multivalent interaction with sialic-acid-
functionalized NPs is expected to competitively inhibit viral 
infection.89  
 The diverse functional possibilities of NCDs allows for a 
variety of approaches for nanocarriers design (see Figure 4). 
Fox et al reported the synthesis of water soluble Au NCDs that 
exhibit micellar properties capable of encapsulating pinacyanol 
chloride.90 These properties make NCDs ideal candidates as 
nanocarriers. Hydrophobic drugs can be loaded onto 
nanocarriers through non-covalent interactions within the 
hydrophobic interior requiring no structural modiﬁcation to the 
drug for drug release.91, 92 Likewise, covalent conjugation to the 
NCDs through cleavable linkages can be used to deliver 
prodrugs to the cell and the drug can then be released by 
external or internal stimuli. Signiﬁcantly, the internal stimuli 
operate in a biologically controlled manner, whereas the 
external stimuli provide spatio-temporal control over the 
release.45 Regardless of the approach used, the tunability of the 
NCDs is crucial for internal or external release. Commonly, a 
covalently conjugated drug to a nanocarrier is better suited for 
specifically targeted drug delivery, while a drug as a 
nanocarrier inclusion complex is readily released and active in 
vitro.93 For example, direct conjugation of functional peptides 
onto AuNPs provides a number of tunable properties that can 
modulate their functions inside living cells. The intracellular 
distributions of the particles changed from the nucleus to the 
endoplasmic reticulum by increasing the peptide density at a 
constant nanoparticle diameter or by increasing the particle 
diameter at a constant peptide density which leads to less 
cellular uptake.94, 95 
 There is a great interest in the development of drug delivery 
systems that could allow an efficient and site-specific transport 
of drugs to the target tissues affected by a disease. A broad 
spectrum of synthetic polymers with structural and architectural 
variations, including linear, star-like, dendritic, and hydrogels is 
currently under investigation. A comparison of dendrimer and 
linear polymer features shows that dendritic polymer 
architecture is advantageous for delivery applications.96 An 
interesting example is described by Contantino et al,97 who 
have presented a general method for incorporating target 
moieties in a well-defined arrangement onto the surface of 
biocompatible nanoparticles of polyester poly(D,L-lactic-co-
glycolic acid) (PLGA) material using Lin´s amine dendrons. In 
this way, it is possible to obtain NPs with a varying degree of 
surface coverage. This new strategy has been successfully 
applied to the preparation of peptide- and b-D-glucose-covered 
NPs. This application is based on the discovery of NPs with a 
regular architecture of a dendrimer able to cross the blood–
brain barrier after systemic administration. Gold nanoparticle-
cored tetraethylene glycol spacer-poly(propyleneimine) 
dendrimers, synthetised by Daniel et al,98, 99 have shown great 
stability in phosphate buﬀer solutions and they were found to 
protonate at pH around 4.5 for their internal tertiary amines, 
which play a crucial role in lysosomal escape during drug 
delivery. Moreover, the primary amine termini provide great 
convenience for direct derivatization with moieties such as 
drugs or targeting entities, for the formation of multifunctional 
drug delivery systems with high payloads.99  
 
 
Figure 4: Cartoon depictions of some possibilities for NCDs as 
nanocarrier 
 
 In addition, one of the most popular modifications of the 
surface of nanocarriers is PEGylation which offers many 
advantages in addition to cytotoxicity reduction such as 
improved bioavailability/oral delivery application related to 
improved biodistribution and pharmacokinetics, enhanced 
solubility, increase in drug loading, sustained and controlled 
delivery of drugs, better transfection efficiency, and tumor 
localization.100 Bergen et al have reported how different 
physicochemical properties, such as size, shape, PEGylation, or 
the ligand, regulate non-speciﬁc versus target-speciﬁc 
uptake.101 Hackley et al 85 have reported the development of a 
cationic dendron with spherical carboxylic groups esterified 
with PEG and then, functionalized with quaternary ammonium 
end groups. These dendrons were used for the preparation of a 
positively charged gold nanoparticle-dendron conjugate and 
they were evaluated by in vivo and in vitro studies. Overall, the 
investigation has confirmed the successful development of 
stable NCDs with excellent stability in biologically relevant test 
media containing proteins and electrolytes, and with a shelf life 
exceeding 6 months. The excellent aqueous stability and 
apparent lack of toxicity for this chemical modification enhance 
the potential use as a test material for investigating interactions 
between positively charged NPs and biocellular and 
biomolecular systems, or as a vehicle for drug delivery. Thus, 
NCDs are promising candidates for a nanoscale test material for 
cellular assays or for use as a drug carrier in nanotherapeutics. 
Rotello et al 102 have demonstrated that the lysine dendron-
functionalized gold nanoparticle was 28 times more effective 
and potent vector than condensing DNA. Most importantly, 
these aminoacid-functionalized NPs showed no cytotoxicity 
when used as transfection agents. These materials were also 
responsive to cellular glutathione level during in vitro 
transfection, providing insight into their mode of activity as 
well as being a potential tool for orthogonal control of 
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transfection.82 Recently, dendronised AuNPs have been used as 
a vector for siRNA delivery suppressed β-gal expression by 
∼50% with minimal toxicity.103 In latter studies, G2-AuNP 
vectors possess the beneﬁts of polymeric delivery vehicles such 
as polyethylenimine, while minimizing toxicity through the use 
of a non-toxic core functionality.  
 Due to their physical properties, superparamagnetic iron 
oxide nanoparticles (SPION) are being extensively studied as a 
part of diagnostic and therapeutic strategies in cancer 
treatments. They can be used as agents for in vitro or in vivo 
imaging, for magnetic drug targeting and/or thermal therapy.76, 
104 The tendency of NPs to aggregate limits their therapeutic 
use in vivo; but surface modifications to produce high positive 
or negative charges can reduce this tendency.105 Thus, magnetic 
nanoparticles as the core in NCDs have recently emerged as a 
simple solution to build novel nanocarriers suitable for 
controlled release. One example is the results described by 
Gunduz et al.106 They have reported the immobilization of 1-
methylimidazole, Polyinosinic-Polycytidylic acid (Poly (I:C)) 
onto different generations of PAMAM dendron-coated 
magnetic nanoparticles (G2 to G7, Dc-MNP) which can be 
targeted to the tumor site under magnetic field. They have 
demonstrated that systems having more functional groups at the 
surface, like higher generations (G7, G6, and G5) of Dc-MNPs 
were found more suitable as a delivery system for Poly (I:C) 
(Figure 5). Further in vitro and in vivo analyses of Poly 
(I:C)/PAMAM magnetic nanoparticles may provide new 
opportunities for the selective targeting and killing of tumor 
cells.  
 
Figure 5: Agarose gel electrophoresis of loading optimization 
Poly (I:C) on G7,G6,G5,G4,G3, and G2DcMNPs at pH 6. Wells 
1–5 demonstrate the control Poly (I:C) and different dilutions. 
Wells 6–11 show the PIC:DcMNP ratio of on G7,G6,G5,G4,G3, 
and G2DcMNPs. 1 in the ratio represents 4 µg of Poly I:C or 
DcMNP, reprinted with kind permission from ref. 106 Copyright 
2013, Springer Science and Business Media. 
 
Schlüter and coworkers26 have reported the stabilization of 
magnetite NPs by dendritic and linear ethylene-glycol-based 
stabilizers with varying generation and chain length, 
respectively. Dendron-stabilized NPs were found to provide 
excellent colloidal stability, despite having a smaller 
hydrodynamic radius and lower degree of soft shell hydration 
when compared to linear PEG analogues. Moreover, for the 
same grafting density and molecular weight of the stabilizers, 
PEG dendron-stabilized NPs show a reversible temperature-
induced aggregation behaviour, in contrast to the essentially 
irreversible aggregation and sedimentation observed for the 
linear PEG analogues. This class of dendritically stabilized NPs 
is believed to have a potential for future biomedical use and 
other applications, in which stability, resistance to (or 
reversible) aggregation, ultra small size (for crossing biological 
barriers or inclusion in responsive artificial membranes), and/or 
high corona density of (bio)active ligands are key for many 
applications, which range from particle-reinforced materials to 
targeted in vitro and in vivo diagnostics. Magnetite NPs 
modiﬁed with the thiol functionalized PAMAM-dendron were 
also successfully used to DNA recovery by magnetic 
separation.107 Martin et al 108 have aimed at modulating the 
uptake of SPIONs by cells for in vitro labeling using polyester 
dendrons having multiple peripheral guanidine groups. This 
dendritic guanidine was found to have good penetrating 
capability upon conjugation with SPIONs and also enhanced 
the cellular uptake (Figure 6). Zhu et al 109 have also employed 
dendronized SPION to load doxorubicin. The anticancer drug 
was conjugated to the peripheral functional groups of a poly (L-
glutamic acid) dendron with pH sensitive hydrazine linkers to 
construct magnetic drug nanocarriers. 
 
a) b)
 
Figure 6: Cells after 2 h incubation with NCDs (nanoparticle 
19). a) Flow cytometry analyses, b) Confocal laser scanning 
microscopy image. Adapted with permission from Ref. 108 
Copyright 2008. American Chemical Society. 
  
In summary, NCDs have emerged as promising drug delivery 
carriers. To accomplish this purpose, NCDs should exhibit high 
water-solubility and drug-loading capacity, low toxicity, 
favorable retention and biodistribution characteristics, 
speciﬁcity, and proper bioavailability. One of the key 
advantages that arise from the dendritic architecture is access to 
the spatial-control over the bioactive-ligand presentation so that 
the targeting capability of the carrier could be optimized. The 
well-defined interior void space between the core and the 
dendritic arms can be used to encapsulate small molecular 
drugs, meanwhile the terminal surface groups of NCDs are 
ideal for bioconjugation of drugs or targeting moieties. The use 
of NCDs can also increase the stability of the payload. Careful 
consideration of the surface modiﬁcation approach is needed to 
avoid any agglomeration after dendronization and yet still 
retain a capability to deliver the payload. Based on our 
understanding of what is known about NCDs characteristics, 
the following strategies may be useful in future studies for their 
use as nanocarriers: (a) focusing on diameters ranging between 
10-30 nm; this size appear to be more likely to maintain an 
equilibrium between the blood circulation and the extracellular 
space, thereby increasing circulation time and facilitating organ 
clearance; (b) identifying organ speciﬁc endothelial cell surface 
markers and target cell speciﬁc markers and design speciﬁc 
afﬁnity peptides or antibodies for these targets and (c) 
designing dendron coatings to functionalize NPs with 
hydrophilic shells with cationic character keeping 
hydrodynamic diameter below the critical size for effective 
clearance. These attributes can be exploited to provide an 
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effective and selective platform to obtain a targeted intracellular 
release of some substances. 
Conclusions 
Here, we have reviewed the most recent advances in the use of 
NCDs in drug delivery systems and highlighted the great 
importance of the dendritic stabilized nanoparticles. These 
hybrid (organic/inorganic) nanoparticles have emerged as a 
simple solution to build “theranostic” systems that are currently 
under intensive investigation for the buildup of novel carriers.  
 We expect this platform to offer a superior performance, 
especially for targeting applications where multivalent 
interactions are the key for specific medical therapies that 
involve the crossing of tissue barriers; a crucial factor in the 
exploitation of the EPR (enhanced permeation effect). The 
higher cost of the synthesis of dendrons is clearly justified by 
this reason. Topics such as surface modiﬁcation, branched 
ligands, and drugs delivery of this type of nanocarriers have 
been discussed. A precise control of the amount and 
distribution of functional groups on the internal and external 
surfaces of NCDs would help increase the loading of 
hydrophobic drugs and control the release timing of the loaded 
drugs. Undoubtedly, progress and development on the design 
and application of NCDs in biomedicine, will shorten the gap to 
obtain successful results in biomedicine in the near future. 
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